News & Updates

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

20 Jul 2024

Use of cycline antibiotics (CAs) is associated with an elevated risk of pseudotumour cerebri syndrome (PTCS) or papilledema, suggests a recent study. However, no statistically significant link between CA use and PTCS development is seen when accounting for confounding factors.

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

20 Jul 2024

Pembrolizumab effective against mucosal melanoma and bladder cancer

12 Jun 2024 by

Findings of two studies presented recently at the European Cancer Congress 2017 (ECCO 2017) demonstrates the effect of the PD-1 inhibitor, pembrolizumab, against a rare form of melanoma and bladder cancer.

Pembrolizumab effective against mucosal melanoma and bladder cancer

12 Jun 2024

Melanoma mortality rates to drop by 2050

12 Jun 2024 by

Mortality rates of melanoma are predicted to fall by 2050, but the number of individuals dying from the disease will increase due to population growth and ageing.

Melanoma mortality rates to drop by 2050

12 Jun 2024

BP-lowering meds spell small increase in eczematous dermatitis rates for older adults

29 May 2024 by

The use of blood pressure (BP)-lowering medications may slightly raise the incidence of eczematous dermatitis among older adults, with the magnitude of effect being largest for calcium channel blockers and diuretic drugs and smallest for angiotensin-converting enzyme (ACE) inhibitors and β-blockers, according to a study.

BP-lowering meds spell small increase in eczematous dermatitis rates for older adults

29 May 2024

48-week data ASSERT odevixibat’s role in ALGS

29 May 2024 by

Pooled analysis of the ASSERT and ASSERT-EXT studies show sustained improvements in multiple parameters with odevixibat in individuals with Alagille syndrome (ALGS), thus reinforcing its role in the treatment of this multisystem genetic disorder.

48-week data ASSERT odevixibat’s role in ALGS

29 May 2024

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

28 May 2024 by

Treatment with dupilumab substantially improves symptoms, quality of life, and other outcomes in patients with atopic hand and foot dermatitis (H/F AD), with an acceptable safety profile, results of a study have shown.

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

28 May 2024

Air pollution linked to higher incidence of atopic dermatitis

26 May 2024

Air pollutants appear to contribute to the increased incidence of atopic dermatitis (AD), results of a Taiwan study have shown.

Air pollution linked to higher incidence of atopic dermatitis

26 May 2024

Air pollution, rainfall influence outpatient visits for atopic dermatitis in SG

25 May 2024 by

Ambient particulate matter concentrations and rainfall are independently associated with the number of outpatient visits for atopic dermatitis in Singapore, according to a study.

Air pollution, rainfall influence outpatient visits for atopic dermatitis in SG

25 May 2024

Erenumab helps with rosacea-associated flushing, erythema

23 Apr 2024

Monthly subcutaneous injections of the anti–CGRP-receptor monoclonal antibody erenumab appear to be beneficial in the management of flushing and chronic redness among individuals with rosacea, according to a study.

Erenumab helps with rosacea-associated flushing, erythema

23 Apr 2024

Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC

23 Apr 2024 by

Switching from FOLFIRI plus cetuximab to FOLFIRI plus bevacizumab leads to acceptable survival outcomes and a reduction in severe dermatological toxicities in patients with RAS wild-type (RASwt) metastatic colorectal cancer (mCRC), according to the results of a single-arm phase II HYBRID trial.

Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC

23 Apr 2024

News & Updates

Filter by Specialty:

Specialty:

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

Cycline antibiotics may increase risk of pseudotumour cerebri syndrome

Pembrolizumab effective against mucosal melanoma and bladder cancer

Pembrolizumab effective against mucosal melanoma and bladder cancer

Melanoma mortality rates to drop by 2050

Melanoma mortality rates to drop by 2050

BP-lowering meds spell small increase in eczematous dermatitis rates for older adults

BP-lowering meds spell small increase in eczematous dermatitis rates for older adults

48-week data ASSERT odevixibat’s role in ALGS

48-week data ASSERT odevixibat’s role in ALGS

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

Dupilumab lessens symptoms, betters life quality in atopic hand and foot dermatitis

Air pollution linked to higher incidence of atopic dermatitis

Air pollution linked to higher incidence of atopic dermatitis

Air pollution, rainfall influence outpatient visits for atopic dermatitis in SG

Air pollution, rainfall influence outpatient visits for atopic dermatitis in SG

Erenumab helps with rosacea-associated flushing, erythema

Erenumab helps with rosacea-associated flushing, erythema

Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC

Switching from cetuximab to bevacizumab associated with acceptable survival, reduced derm toxicity in mCRC